Company news: Gilead, Pfizer and Wolters Kluwer

Share this article:

Two potential blockbusters in the pharma pipeline took another step toward reaching market. US regulatory authorities assigned August 2012 PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib. Quad is a single-tablet HIV regimen containing four agents, while tofacitinib is set to become the first oral rheumatoid arthritis drug to enter the injectable RA space. NDAs for both drugs had been submitted earlier this year.

Wolters Kluwer said it completed the sale of its pharma-related marketing & publishing services business to Springer Science+Business Media. The sale, announced in November, is part of Wolters Kluwer's strategy to focus on core health markets through its Wolters Kluwer Health & Pharma Solutions division.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.